United States: EU Court Confirms European Commission's Decision On Pay-For-Delay Agreements


On 8 September 2016, the General Court of the European Union upheld the European Commission's decision in which the antitrust regulator imposed fines of approximately EUR 150 million on Lundbeck and a number of generic companies for entering into reverse settlement agreements which delayed the entry of cheaper generic versions of a blockbuster antidepressant.

The Commission had first hinted that patent settlement agreements causing delayed generic entry might be problematic in its 2009 report on the Pharmaceutical Sector Inquiry.  

In Depth

The Commission launched a formal antitrust investigation against Lundbeck in January 2010, only six months after publishing the Final Report of the Pharmaceutical Sector Inquiry. The investigation was concluded on 19 June 2013, when the Commission imposed a fine of EUR 93 million on Lundbeck, and fines amounting to EUR 52 million on several generic manufacturers, for breaching Article 101(1) of the Treaty on the Functioning of the European Union (TFEU).

The Commission found that, shortly prior to the expiry of the underlying intellectual property protection, the Danish firm agreed with its generic competitors to delay the market entry of cheaper generic versions of Lundbeck's branded Citalopram, a popular anti-depressant. In return for not entering the market, the generic producers obtained "substantial payments and other inducements" from Lundbeck, often corresponding to the profits that the generics could have expected following entry. In particular, the value transfers took the form of direct lump-sum payments and acquisitions of generic stock for subsequent destruction.

The Commission held that the reverse payment settlement agreements were in violation of Article 101(1) TFEU "by object" and that Lundbeck's reverse payments served to eliminate the generics' incentives to continue their independent efforts to enter the market. Furthermore, the Commission noted that acceptance of the limitations was achieved not by the strength of Lundbeck's patents, but by the transfer of value from Lundbeck to each of the generic companies.

Appeal to the General Court

Lundbeck brought an appeal against the Commission's decision arguing, inter alia, that (i) Lundbeck and the generic companies that were parties to the agreements were not potential competitors under Article 101(1) TFEU, and (ii) the Commission's conclusion that the patent settlement agreements restricted competition by object under Article 101(1) rests on a wrongful application of the established principles on restrictions by object.

In the 8 September 2016 judgment, the General Court dismissed all of Lundbeck's grounds of appeal and upheld the Commission's 2013 decision.

Potential Competition

The General Court held that the Commission had carried out a careful examination of the real, concrete possibilities that the generic companies had of entering the market, and had based its findings on objective evidence. The Court agreed with the Commission's finding that Lundbeck's patents did not necessarily constitute insurmountable barriers for the generic manufacturers which were willing and ready to enter the market, and which had already made considerable investments to do so. This apparent readiness to enter the market, according to the General Court, represented the expression of potential competition.

The Court concluded that, in order to establish the existence of potential competition, it is not necessary to demonstrate with certainty that the generic manufacturers would have entered the market and that that entry would inevitably have been successful, but only that they had real, concrete possibilities in that respect.  

"By Object" Infringement

The General Court also held that the Commission was correct in considering that the very existence of payments from the originator to the generic, and the disproportionate nature of those payments, were relevant factors in establishing whether the agreements constituted restrictions of competition "by object". This is because, through those payments, the originator provided an incentive to the generics not to continue their independent efforts to enter the market. The Court also pointed out that an agreement may be regarded as having a restrictive object even if it does not have the restriction of competition as its sole aim but also pursues other legitimate objectives (such as the settlement of a dispute).

The General Court held that the reverse payment settlement agreements at issue were comparable to market exclusion agreements, which are among the most serious restrictions of competition, and that the exclusion of competitors from the market constitutes an extreme form of market sharing and limitation of production. The Court concluded that such agreements may, by their very nature, be regarded as restricting competition in a sufficiently serious manner as to be classified as a restriction "by object", which by its very nature cannot benefit from the possibility of exemption under Article 101(3) TFEU.

The General Court also found that Lundbeck had failed to demonstrate that these arrangements were needed to protect its intellectual property rights.


Many pharmaceutical companies will find the General Court's judgment difficult to accept. The imposition of a blanket ban on reverse settlement agreements appears to be predicated on the assumption that the only purpose of such settlements is to delay unduly the entry of a generic product and to prolong the exclusivity enjoyed by the originator.

The presumption that a reverse settlement agreement is less competitive than the expected outcome of the litigation that is being settled appears at least controversial. By condemning reverse settlements, the Commission is implying that the generic company would have successfully challenged (i.e., invalidated) the originator's patent rights, and that the settlement is therefore an artificial way of preserving a patent that ought not to confer upon its holder any exclusivities. Given the inherent complexities and uncertainties attached to patent litigation, this is an assumption that should be difficult for an antitrust regulator to make.


The General Court's decision is not final, as recipients of the judgment may still bring an appeal to the Court of Justice questioning the General Court's stance on reverse payment settlements as well as the Court's approach to restriction "by object". Lundbeck already issued a press release stating that it strongly disagrees with the ruling and that it is considering whether to bring an appeal before the Court of Justice.

This judgment will have important implications for the remaining pay-for-delay appeals currently pending in Luxembourg, as well as for the related damages action before the UK Competition Appeal Tribunal.  

Originators and generics wishing to discontinue pending patent litigation should carefully consider the terms and conditions of their settlement agreements, with particular attention given to the overall scope of such agreements and any value transfer that may be construed, where relevant, as an inducement to ensure that a contract party delays or cancels market entry. 

EU Court Confirms European Commission's Decision On Pay-For-Delay Agreements

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.